New Caledonia
- Overview
- Comorbidities
Loading data – please wait …
Oesophageal cancer
Men, 2018
| Age: | 20+ |
| References: | Global Cancer Observatory, Cancer incidence rates http://gco.iarc.fr/ (last accessed 30th June 2020) |
| Definitions: | Estimated age-standardized incidence rates (World) in 2018, oesophagus, adults ages 20+. ASR (World) per 100,000 |
Women, 2018
| Age: | 20+ |
| References: | Global Cancer Observatory, Cancer incidence rates http://gco.iarc.fr/ (last accessed 30th June 2020) |
| Definitions: | Estimated age-standardized incidence rates (World) in 2018, oesophagus, adults ages 20+. ASR (World) per 100,000 |
Breast cancer
Women, 2018
| Age: | 20+ |
| References: | Global Cancer Observatory, Cancer incidence rates http://gco.iarc.fr/ (last accessed 30th June 2020) |
| Definitions: | Estimated age-standardized incidence rates (World) in 2018, breast, females, ages 20+. ASR (World) per 100,000 |
Colorectal cancer
Men, 2018
| Age: | 20+ |
| References: | Global Cancer Observatory, Cancer incidence rates http://gco.iarc.fr/ (last accessed 30th June 2020) |
| Definitions: | Estimated age-standardized incidence rates (World) in 2018, colorectum, adults, ages 20+. ASR (World) per 100,000 |
Women, 2018
| Age: | 20+ |
| References: | Global Cancer Observatory, Cancer incidence rates http://gco.iarc.fr/ (last accessed 30th June 2020) |
| Definitions: | Estimated age-standardized incidence rates (World) in 2018, colorectum, adults, ages 20+. ASR (World) per 100,000 |
Pancreatic cancer
Men, 2018
| Age: | 20+ |
| References: | Global Cancer Observatory, Cancer incidence rates http://gco.iarc.fr/ (last accessed 30th June 2020) |
| Definitions: | Estimated age-standardized incidence rates (World) in 2018, pancreas, adults, ages 20+. ASR (World) per 100,000 |
Women, 2018
| Age: | 20+ |
| References: | Global Cancer Observatory, Cancer incidence rates http://gco.iarc.fr/ (last accessed 30th June 2020) |
| Definitions: | Estimated age-standardized incidence rates (World) in 2018, pancreas, adults, ages 20+. ASR (World) per 100,000 |
Gallbladder cancer
Men, 2018
| Age: | 20+ |
| References: | Global Cancer Observatory, Cancer incidence rates http://gco.iarc.fr/ (last accessed 30th June 2020) |
| Definitions: | Estimated age-standardized incidence rates (World) in 2018, gallbladder, adults, ages 20+. ASR (World) per 100,000 |
Women, 2018
| Age: | 20+ |
| References: | Global Cancer Observatory, Cancer incidence rates http://gco.iarc.fr/ (last accessed 30th June 2020) |
| Definitions: | Estimated age-standardized incidence rates (World) in 2018, gallbladder, adults, ages 20+. ASR (World) per 100,000 |
Kidney cancer
Men, 2018
| Age: | 20+ |
| References: | Global Cancer Observatory, Cancer incidence rates http://gco.iarc.fr/ (last accessed 30th June 2020) |
| Definitions: | Estimated age-standardized incidence rates (World) in 2018, kidney, adults, ages 20+. ASR (World) per 100,000 |
Women, 2018
| Age: | 20+ |
| References: | Global Cancer Observatory, Cancer incidence rates http://gco.iarc.fr/ (last accessed 30th June 2020) |
| Definitions: | Estimated age-standardized incidence rates (World) in 2018, kidney, adults, ages 20+. ASR (World) per 100,000 |
Cancer of the uterus
Women, 2018
| Age: | 20+ |
| References: | Global Cancer Observatory, Cancer incidence rates http://gco.iarc.fr/ (last accessed 30th June 2020) |
| Definitions: | Estimated age-standardized incidence rates (World) in 2018, cervix uteri, females, ages 20+. ASR (World) per 100,000 |
Diabetes prevalence
Adults, 2019
| Age: | 20-79 |
| References: | Reproduced with kind permission International Diabetes Federation. IDF Diabetes Atlas, 9th edn. Brussels,Belgium: 2019. Available at: https://www.diabetesatlas.org |
| Definitions: | Diabetes age-adjusted comparative prevalence (%). |
Adults, 2017
| References: | Reproduced with kind permission of IDF, International Diabetes Federation. IDF Diabetes Atlas, 8th edition. Brussels, Belgium: International Diabetes Federation, 2017. http://www.diabetesatlas.org |
| Definitions: | Diabetes age-adjusted comparative prevalence (%). |
